InfuSystem (INFU) 10-Q 12 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	INFU
Entity Registrant Name	InfuSystem Holdings, Inc
Entity Central Index Key	1337013
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		22,359,756

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current Assets:
Cash and cash equivalents	$3,224	$515
Accounts receivable, less allowance for doubtful accounts of $4,831 and $4,739 at March 31, 2015 and December 31, 2014, respectively	11,498	10,300
Inventory	1,979	1,758
Other current assets	1,129	633
Deferred income taxes	2,252	2,252
Total Current Assets	20,082	15,458
Medical Equipment held for sale or rental	2,671	2,255
Medical equipment in rental service, net of accumulated depreciation	21,908	19,814
Property & equipment, net of accumulated depreciation	2,457	2,451
Deferred debt issuance costs, net	147	1,194
Intangible assets, net	25,852	25,073
Deferred income taxes	14,143	13,756
Other assets	206	212
Total Assets	87,466	80,213
Current Liabilities:
Accounts payable	5,367	5,215
Current portion of long-term debt	5,537	6,452
Other current liabilities	2,157	3,062
Total Current Liabilities	13,061	14,729
Long-term debt, net of current portion	28,080	19,032
Total Liabilities	41,141	33,761
Stockholders' Equity:
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued
Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 22,506,421 and 22,308,730, respectively, as of March 31, 2015 and 22,506,421 and 22,308,730, respectively, as of December 31, 2014	2	2
Additional paid-in capital	90,442	90,155
Retained deficit	-44,119	-43,705
Total Stockholders' Equity	46,325	46,452
Total Liabilities and Stockholders' Equity	$87,466	$80,213

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$4,831	$4,739
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	22,506,421	22,506,421
Common stock, shares outstanding	22,308,730	22,308,730

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net revenues:
Rentals	$15,139	$14,850
Product Sales	1,586	2,392
Net revenues	16,725	17,242
Cost of revenues:
Cost of revenues - Product, service and supply costs	3,015	2,890
Cost of revenues - Pump depreciation and disposals	1,621	2,276
Gross profit	12,089	12,076
Selling, general and administrative expenses:
Provision for doubtful accounts	1,194	2,107
Amortization of intangibles	631	629
Selling and marketing	2,737	2,655
General and administrative	5,975	4,909
Total selling, general and administrative	10,537	10,300
Operating income	1,552	1,776
Other income (expense):
Interest expense	-672	-827
Loss on extinguishment of long term debt	-1,599
Other income (expense)	19	-17
Total other expense	-2,252	-844
(Loss) income before income taxes	-700	932
Income tax benefit (expense)	285	-349
Net (loss) income	($415)	$583
Net (loss) income per share:
Basic	($0.02)	$0.03
Diluted	($0.02)	$0.03
Weighted average shares outstanding:
Basic	22,308,730	21,972,739
Diluted	22,308,730	22,456,143

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Cash Flows [Abstract]
NET CASH USED IN OPERATING ACTIVITIES	($1,392)	($636)
INVESTING ACTIVITIES
Purchase of medical equipment and property	-3,670	-1,127
Proceeds from sale of medical equipment and property	1,118	1,252
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES	-2,552	125
FINANCING ACTIVITIES
Principal payments on revolving credit facility, term loans and capital lease obligations	-38,633	-14,394
Cash proceeds from revolving credit facility	45,980	14,263
Debt issuance costs	-147
Principal payments on capital lease obligation	-547
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	6,653	-131
Net change in cash and cash equivalents	2,709	-642
Cash and cash equivalents, beginning of period	515	1,138
Cash and cash equivalents, end of period	$3,224	$496

Basis_of_Presentation_Nature_o

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	1. Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies
	The terms “InfuSystem”, “the Company”, “we”, “our” and “us” are used herein refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services. The Company services hospitals, oncology practices and other alternative site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support, and also operates pump repair Centers of Excellence in Michigan, Kansas, California, Texas, and Ontario, Canada.
	The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the SEC.
	The consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

Medical_Equipment_and_Property

Medical Equipment and Property	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Medical Equipment and Property	2. Medical Equipment and Property
	Medical equipment consisted of the following as of March 31, 2015 and December 31, 2014 (in thousands):
		March 31,			December 31,
		2015			2014
	Medical Equipment held for sale or rental	$	2,671		$	2,255
	Medical Equipment in rental service		45,849			43,246
	Medical Equipment in rent service—pump reserve		(145	)		(121	)
	Accumulated depreciation		(23,796	)		(23,311	)
	Medical Equipment in rental service—net		21,908			19,814
	Total	$	24,579		$	22,069
	Depreciation expense for medical equipment for the three months ended March 31, 2015 was $1.0 million compared to $0.7 million for the same prior year period, which was recorded in cost of revenues – pump depreciation and disposals, respectively.
	Depreciation expense for property and equipment for the three months ended March 31, 2015 was $0.1 million, which was consistent with the same prior year period. This expense was recorded in general and administrative expenses.

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	3. Intangible Assets
	The carrying amount and accumulated amortization of intangible assets as of March 31, 2015 and December 31, 2014, are as follows (in thousands):
		March 31, 2015
		Gross		Accumulated		Net
		Assets		Amortization
	Nonamortizable intangible assets
	Trade names	$	2,000	$	—	$	2,000
	Amortizable intangible assets
	Physician and customer relationships		32,865		15,303		17,563
	Non-competition agreements		848		816		32
	Software		7,682		1,424		6,257
	Total nonamortizable and amortizable intangible assets	$	43,395	$	17,543	$	25,852
		31-Dec-14
		Gross		Accumulated		Net
		Assets		Amortization
	Nonamortizable intangible assets
	Trade names	$	2,000	$	—	$	2,000
	Amortizable intangible assets
	Physician and customer relationships		32,865		14,755		18,111
	Non-competition agreements		848		778		70
	Software		6,299		1,407		4,892
	Total nonamortizable and amortizable intangible assets	$	42,012	$	16,940	$	25,073
	Amortization expense for the three months ended March 31, 2015 was $0.6 million, which was consistent with the same prior year period. Expected annual amortization expense for intangible assets recorded as of March 31, 2015, is as follows (in thousands):
		4/1-		2016		2017		2018		2019		2020 and
		12/31/15										thereafter
	Amortization expense	$	2,580	$	4,290	$	4,255	$	3,381	$	2,191	$	7,155

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt	4. Debt
	On March 23, 2015, the Company and its direct and indirect subsidiaries entered into a credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as lender (the “Lender”). The borrowers under the Credit Agreement are the Company, InfuSystem Holdings USA, Inc., a Delaware corporation (“Holdings”), InfuSystem, Inc., a California corporation (“InfuSystem”), First Biomedical, Inc., a Kansas corporation (“FBI”), and IFC LLC, a Delaware limited liability company (“IFC” and, collectively with the Company, Holdings, InfuSystem and FBI, the “Borrowers”). The Credit Agreement consists of a $27.0 million Term Loan A, up to $8.0 million Term Loan B and a $10.0 million revolving credit facility (the “Revolver”), all of which mature on March 23, 2020, collectively (the “Credit Facility”).
	On March 23, 2015, the Borrowers drew $27.0 million under the Term A Loan to repay and terminate the previously existing credit facility under the credit agreement dated November 30, 2012, as amended, by and among the Company, its direct and indirect subsidiaries, Wells Fargo Bank, National Association, as administrative agent, and certain lenders party thereto (the “WF Facility”). Term Loan B was unfunded at closing and as of March 31, 2015 and is available for the Company to draw upon for a period of 180 days post-closing in respect of a Permitted Acquisition. As of March 31, 2015, interest on the Credit Facility is payable at the Company’s choice of Eurodollar Loan at a per annum rate equal to LIBOR plus a margin ranging from 2.00% to 2.50% or CBFR Loans which bears interest at a per annum rate equal to (a) the Lender’s prime rate or (b) LIBOR for a 30 day interest period plus 2.50%, in each case plus a margin ranging from -0.75% to -0.25%. The availability under the Revolver is based upon the Company’s eligible accounts receivable and eligible inventory and is broken down as follows (in thousands):
			March 31,			December 31,
			2015			2014
	Revolver:
	Gross Availability		$	10,000		$	7,432
	Outstanding Draws			(1,000	)		(566	)
	Letter of Credit			—			(282	)
	Availability on Revolver		$	9,000		$	6,584
	To secure repayment of the obligations of the Borrowers, each Borrower has granted to the Lender, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers. In addition, the Company has pledged the shares of InfuSystem Holdings USA, Inc. (“Holdings USA”) and Holdings USA has pledged the shares of each of InfuSystem, Inc. and First Biomedical, Inc. and the equity interests of IFC LLC to the Lender, for the benefit of the secured parties, to further secure the obligations under the Credit Agreement.
	The Credit Agreement contains certain affirmative and negative covenants typical for credit facilities of this type. These covenants (subject to certain agreed and customary exceptions set forth in the Credit Agreement) restrict or limit subject to the Lender’s prior consent, and in some cases prohibit, the Borrowers from engaging in certain actions, including its ability to, among other things: (i) incur indebtedness; (ii) create liens; (iii) engage in mergers, consolidations, liquidations or dissolutions; (iv) engage in acquisitions; (v) dispose of assets; (vi) pay dividends and distributions or repurchase capital stock or make other restricted payments; (vii) make investments, loans, guarantees or advances; (viii) engage in certain transactions with affiliates; (ix) enter into sale and leaseback transactions; (x) enter into hedging agreements; (xi) enter into agreements that restrict distributions from subsidiaries; and (xii) change their fiscal year.
	In addition, the Credit Agreement requires the Borrowers to maintain the following financial covenant obligations:
		(i)	a minimum fixed charge coverage ratio of 1.25:1.00;
		(ii)	a maximum total leverage ratio ranging from 3.00:1.00 to 2.25:1.00 during specified periods; and
		(iii)	a minimum net worth of $37.5 million.
	The Company occasionally enters into capital leases to finance the purchase of ambulatory infusion pumps. The pumps are capitalized into medical equipment in rental service at their fair market value, which equals the value of the future minimum lease payments and are depreciated over the useful life of the pumps.
	The Company had approximate future maturities of loans and capital leases as of March 31, 2015 as follows (in thousands):
			2015			2016			2017		2018				2019				2020				Total
	Term Loans		$	1,930		$	3,860		$	3,860	$	3,860			$	3,860			$	9,630			$	27,000
	Revolver			—			1,000			—		—				—				—				1,000
	Capital Leases			1,977			2,285			1,234		121				—				—				5,617
	Total		$	3,907		$	7,145		$	5,094	$	3,981			$	3,860			$	9,630			$	33,617
	The following is a breakdown of the Company’s current and long-term debt (including capital leases) as of March 31, 2015 and December 31, 2014 (in thousands):
	March 31, 2015										December 31, 2014
			Current			Long-Term			Total				Current				Long-Term				Total
			Portion of			Debt							Portion of				Debt
			Long-Term										Long-
			Debt										Term Debt
	Term Loans		$	2,895		$	24,105		$	27,000	Term Loans		$	4,238			$	15,849			$	20,087
	Revolver			—			1,000			1,000	Revolver			—				566				566
	Capital Leases			2,642			2,975			5,617	Capital Leases			2,214				2,617				4,831
	Total		$	5,537		$	28,080		$	33,617	Total		$	6,452			$	19,032			$	25,484
	The Company’s Credit Facility is collateralized by substantially all of its assets and shares of the Company and requires the Company comply with covenants, including but not limited to, financial covenants relating to the satisfaction, on a quarterly and annual basis for the duration of the Credit Facility, of a total leverage ratio, a fixed charge coverage ratio and a net worth level. As of March 31, 2015, the Company was in compliance with all such covenants and expect to remain in compliance for the next 12 months.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	5. Income Taxes
	During the three months ended March 31, 2015 and 2014, we recorded an income tax benefit of $0.3 million and an expense of $0.3 million, respectively. In computing its income tax provision, the Company estimates its effective tax rate for the full year and applies that rate to income earned though the reporting period. The effective income tax rate was 40.8% and 37.4% for the quarters ended March 31, 2015 and 2014, respectively.

Commitments_Contingencies_and_

Commitments, Contingencies and Litigation	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	6. Commitments, Contingencies and Litigation
	From time to time in the ordinary course of its business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The Company has insurance policies covering potential losses where such coverage is cost effective. The Company is not, at this time, involved in any legal proceedings that the Company believes could have a material effect on the Company’s financial condition, results of operations or cash flows.

Loss_Earnings_Per_Share

(Loss) Earnings Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
(Loss) Earnings Per Share	7. (Loss) Earnings Per Share
	Basic (loss) income per share is computed by dividing net (loss) income by the weighted average number of common shares outstanding during the period. Diluted (loss) income per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted (loss) income per share computations:
		Three Months Ended
		March 31
		2015			2014
	Numerator:
	Net (loss) income (in thousands)	$	(415	)	$	583
	Denominator:
	Weighted average common shares outstanding:
	Basic		22,308,730			21,972,739
	Dilutive effect of restricted shares, options and non-vested share awards		446,283			483,404
	Diluted		22,755,013			22,456,143
	Net (loss) income per share:
	Basic	$	(0.02	)	$	0.03
	Diluted	$	(0.02	)	$	0.03
	For the three months ended March 31, 2015 and 2014, 0.3 million and 0.1 million, respectively, of stock options were not included in the calculation because they would have an anti-dilutive effect.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events
	The Company has evaluated subsequent events through the date of issuance for the condensed consolidated financial statements.
	On April 21, 2015, the Company announced that it closed on the acquisition of substantially all of the assets of Ciscura Holding Company, Inc., and its subsidiaries (“Ciscura”). Ciscura, based in Alpharetta, GA, was a privately-held Southeastern regional provider of ambulatory infusion pumps and services to medical facilities.
	The Company acquired approximately 1,600 infusion pumps from Ciscura, its four person field sales team, as well as its facilities management personnel, which will become the foundation of the Company’s new Southeast facility, located near Atlanta, Georgia. With this new regional facility, the Company will be in close proximity to a number of its largest existing customers, in addition to new customers previously serviced by Ciscura, enabling same day service for equipment and supplies to much of the Southeast region.
	The Company currently estimates the value of the acquisition at less than $5 million. This amount is based upon the Company’s current estimate of the final number of pumps acquired and the associated treatments, which will be generated during the 90 day period post-closing from the approximately 106 medical facility relationships Ciscura had prior to the acquisition. The Company has estimated that the associated integration and transaction costs will be approximately $0.5 million.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements and Developments	3 Months Ended
	Mar. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements and Developments	9. Recent Accounting Pronouncements and Developments
	In April 2015, the Financial Accounting Standards Board (“FASB”) issued additional guidance on Intangibles – Goodwill and Other—Internal-Use Software and how a customer should account for fees paid in a cloud computing arrangement. Guidance for determining whether an arrangement includes the sale or license of software already existed for cloud service providers. The new guidance requires that if a cloud computing arrangement includes a software license, the customer should account for the software license element in the arrangement consistent with the acquisition of software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This new standard does not change the GAAP for a customer’s accounting for service contracts. The effective date of this new standard is for annual periods, including interim within those annual periods, beginning after December 15, 2015. The Company may elect a retrospective or prospective transition. The Company is currently evaluating its Information Technology (“IT”) arrangements and their applicability to this new guidance.
	In May 2014, the FASB issued a comprehensive new standard, which amends revenue recognition principles and provides a single set of criteria for revenue recognition among all industries. The new standard provides a five step framework whereby revenue is recognized when promised goods or services are transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosure relating to revenue recognition in both the interim and annual periods. On April 1, 2015, the FASB proposed to defer the effective date for annual reporting periods beginning after December 15, 2017 and allows for adoption using a full retrospective method, or a modified retrospective method. Early adoption is allowed but not before the original public organization date of December 15, 2016. The Company is currently assessing the method of adoption and the expected impact the new standard has on our financial position and results of operations.
	In August 2014, the FASB issued guidance requiring management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements. Entities must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The disclosure requires identifying the principal conditions and events contributing to the “doubt” to continue as a going concern, as well as management’s evaluations and plans to try to alleviate these uncertainties. This guidance is effective for annual reporting periods, within those annual periods ending after December 15, 2016. The Company is currently evaluating the impact of adopting this standard to determine the impact, if any, it may have on its current practices.
	In April 2014, the FASB issued guidance on Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity (“ASU 2014-08”), which provides guidance regarding the definition of a discontinued operation and the required disclosures. The new guidance defines a discontinued operation as a component or group of components that is disposed of or is classified as held for sale and represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. A strategic shift could include a disposal of (1) a major geographical area of operations, (2) a major line of business, (3) a major equity method investment, or (4) other major parts of an entity. In addition, having significant continuing involvement with a component after a disposal or failing to eliminate the operations or cash flows of a disposed component from an entity’s ongoing operations will no longer preclude presentation as a discontinued operation. There will be new disclosures required related to discontinued operations and to disposals of individually significant components that do not qualify as discontinued operations. ASU 2014-08 is effective for reporting periods beginning after December 15, 2014. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. ASU 2014-08 applies prospectively to new disposals of components and new classifications as held for sale and is not expected to have a significant impact on the presentation of the Company’s financial statements or disclosures.

Recent_Accounting_Pronouncemen1

Recent Accounting Pronouncements and Developments (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements and Developments	In April 2015, the Financial Accounting Standards Board (“FASB”) issued additional guidance on Intangibles – Goodwill and Other—Internal-Use Software and how a customer should account for fees paid in a cloud computing arrangement. Guidance for determining whether an arrangement includes the sale or license of software already existed for cloud service providers. The new guidance requires that if a cloud computing arrangement includes a software license, the customer should account for the software license element in the arrangement consistent with the acquisition of software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This new standard does not change the GAAP for a customer’s accounting for service contracts. The effective date of this new standard is for annual periods, including interim within those annual periods, beginning after December 15, 2015. The Company may elect a retrospective or prospective transition. The Company is currently evaluating its Information Technology (“IT”) arrangements and their applicability to this new guidance.
	In May 2014, the FASB issued a comprehensive new standard, which amends revenue recognition principles and provides a single set of criteria for revenue recognition among all industries. The new standard provides a five step framework whereby revenue is recognized when promised goods or services are transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosure relating to revenue recognition in both the interim and annual periods. On April 1, 2015, the FASB proposed to defer the effective date for annual reporting periods beginning after December 15, 2017 and allows for adoption using a full retrospective method, or a modified retrospective method. Early adoption is allowed but not before the original public organization date of December 15, 2016. The Company is currently assessing the method of adoption and the expected impact the new standard has on our financial position and results of operations.
	In August 2014, the FASB issued guidance requiring management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements. Entities must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The disclosure requires identifying the principal conditions and events contributing to the “doubt” to continue as a going concern, as well as management’s evaluations and plans to try to alleviate these uncertainties. This guidance is effective for annual reporting periods, within those annual periods ending after December 15, 2016. The Company is currently evaluating the impact of adopting this standard to determine the impact, if any, it may have on its current practices.
	In April 2014, the FASB issued guidance on Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity (“ASU 2014-08”), which provides guidance regarding the definition of a discontinued operation and the required disclosures. The new guidance defines a discontinued operation as a component or group of components that is disposed of or is classified as held for sale and represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. A strategic shift could include a disposal of (1) a major geographical area of operations, (2) a major line of business, (3) a major equity method investment, or (4) other major parts of an entity. In addition, having significant continuing involvement with a component after a disposal or failing to eliminate the operations or cash flows of a disposed component from an entity’s ongoing operations will no longer preclude presentation as a discontinued operation. There will be new disclosures required related to discontinued operations and to disposals of individually significant components that do not qualify as discontinued operations. ASU 2014-08 is effective for reporting periods beginning after December 15, 2014. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. ASU 2014-08 applies prospectively to new disposals of components and new classifications as held for sale and is not expected to have a significant impact on the presentation of the Company’s financial statements or disclosures.

Medical_Equipment_and_Property1

Medical Equipment and Property (Tables)	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Summary of Medical Equipment	Medical equipment consisted of the following as of March 31, 2015 and December 31, 2014 (in thousands):
		March 31,			December 31,
		2015			2014
	Medical Equipment held for sale or rental	$	2,671		$	2,255
	Medical Equipment in rental service		45,849			43,246
	Medical Equipment in rent service—pump reserve		(145	)		(121	)
	Accumulated depreciation		(23,796	)		(23,311	)
	Medical Equipment in rental service—net		21,908			19,814
	Total	$	24,579		$	22,069

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets	The carrying amount and accumulated amortization of intangible assets as of March 31, 2015 and December 31, 2014, are as follows (in thousands):
		March 31, 2015
		Gross		Accumulated		Net
		Assets		Amortization
	Nonamortizable intangible assets
	Trade names	$	2,000	$	—	$	2,000
	Amortizable intangible assets
	Physician and customer relationships		32,865		15,303		17,563
	Non-competition agreements		848		816		32
	Software		7,682		1,424		6,257
	Total nonamortizable and amortizable intangible assets	$	43,395	$	17,543	$	25,852
		31-Dec-14
		Gross		Accumulated		Net
		Assets		Amortization
	Nonamortizable intangible assets
	Trade names	$	2,000	$	—	$	2,000
	Amortizable intangible assets
	Physician and customer relationships		32,865		14,755		18,111
	Non-competition agreements		848		778		70
	Software		6,299		1,407		4,892
	Total nonamortizable and amortizable intangible assets	$	42,012	$	16,940	$	25,073
Schedule of Expected Annual Amortization Expense for Intangible Assets	Expected annual amortization expense for intangible assets recorded as of March 31, 2015, is as follows (in thousands):
		4/1-		2016		2017		2018		2019		2020 and
		12/31/15										thereafter
	Amortization expense	$	2,580	$	4,290	$	4,255	$	3,381	$	2,191	$	7,155

Debt_Tables

Debt (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Summary of Revolver Based upon Company's Eligible Accounts Receivable and Inventory	The availability under the Revolver is based upon the Company’s eligible accounts receivable and eligible inventory and is broken down as follows (in thousands):
		March 31,			December 31,
		2015			2014
	Revolver:
	Gross Availability	$	10,000		$	7,432
	Outstanding Draws		(1,000	)		(566	)
	Letter of Credit		—			(282	)
	Availability on Revolver	$	9,000		$	6,584
Summary of Future Maturities of Loans and Capital Leases	The Company had approximate future maturities of loans and capital leases as of March 31, 2015 as follows (in thousands):
		2015			2016			2017		2018				2019				2020				Total
	Term Loans	$	1,930		$	3,860		$	3,860	$	3,860			$	3,860			$	9,630			$	27,000
	Revolver		—			1,000			—		—				—				—				1,000
	Capital Leases		1,977			2,285			1,234		121				—				—				5,617
	Total	$	3,907		$	7,145		$	5,094	$	3,981			$	3,860			$	9,630			$	33,617
Summary of Company's Current and Long-Term Debt (Including Capital Leases)	The following is a breakdown of the Company’s current and long-term debt (including capital leases) as of March 31, 2015 and December 31, 2014 (in thousands):
	March 31, 2015									December 31, 2014
		Current			Long-Term			Total				Current				Long-Term				Total
		Portion of			Debt							Portion of				Debt
		Long-Term										Long-
		Debt										Term Debt
	Term Loans	$	2,895		$	24,105		$	27,000	Term Loans		$	4,238			$	15,849			$	20,087
	Revolver		—			1,000			1,000	Revolver			—				566				566
	Capital Leases		2,642			2,975			5,617	Capital Leases			2,214				2,617				4,831
	Total	$	5,537		$	28,080		$	33,617	Total		$	6,452			$	19,032			$	25,484

Loss_Earnings_Per_Share_Tables

(Loss) Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Numerators and Denominators of Basic and Diluted (Loss) Income per Share	The following table reconciles the numerators and denominators of the basic and diluted (loss) income per share computations:
		Three Months Ended
		March 31
		2015			2014
	Numerator:
	Net (loss) income (in thousands)	$	(415	)	$	583
	Denominator:
	Weighted average common shares outstanding:
	Basic		22,308,730			21,972,739
	Dilutive effect of restricted shares, options and non-vested share awards		446,283			483,404
	Diluted		22,755,013			22,456,143
	Net (loss) income per share:
	Basic	$	(0.02	)	$	0.03
	Diluted	$	(0.02	)	$	0.03

Medical_Equipment_and_Property2

Medical Equipment and Property - Summary of Medical Equipment (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Medical Equipment And Property [Abstract]
Medical Equipment held for sale or rental	$2,671	$2,255
Medical Equipment in rental service	45,849	43,246
Medical Equipment in rent service-pump reserve	-145	-121
Accumulated depreciation	-23,796	-23,311
Medical Equipment in rental service-net	21,908	19,814
Total	$24,579	$22,069

Medical_Equipment_and_Property3

Medical Equipment and Property - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense for medical equipment	$1	$0.70
Depreciation expense for property and equipment (other than medial equipment) recorded in general and administrative expenses	$0.10	$0.10

Intangible_Assets_Summary_of_C

Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Total nonamortizable and amortizable intangible assets, Gross Assets	$43,395	$42,012
Total nonamortizable and amortizable intangible assets, Accumulated Amortization	17,543	16,940
Total nonamortizable and amortizable intangible assets, Net	25,852	25,073
Physician and Customer Relationships [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	32,865	32,865
Amortizable intangible assets, Accumulated Amortization	15,303	14,755
Amortizable intangible assets, Net	17,563	18,111
Non-Competition Agreements [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	848	848
Amortizable intangible assets, Accumulated Amortization	816	778
Amortizable intangible assets, Net	32	70
Software [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	7,682	6,299
Amortizable intangible assets, Accumulated Amortization	1,424	1,407
Amortizable intangible assets, Net	6,257	4,892
Trade Names [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Nonamortizable intangible assets	$2,000	$2,000

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$631	$629

Intangible_Assets_Schedule_of_

Intangible Assets - Schedule of Expected Annual Amortization Expense for Intangible Assets (Detail) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense for remaining fiscal year, 2015	$2,580
Amortization expense, 2016	4,290
Amortization expense, 2017	4,255
Amortization expense, 2018	3,381
Amortization expense, 2019	2,191
Amortization expense, 2020 and thereafter	$7,155

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 23, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Credit facility, maturity date	23-Mar-20
Eurodollar [Member]
Line of Credit Facility [Line Items]
Interest on the credit facility, description	Eurodollar Loan at a per annum rate equal to LIBOR plus a margin ranging from 2.00% to 2.50%
Maximum [Member] | Eurodollar LIBOR Rate [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate	2.50%
Minimum [Member] | Eurodollar LIBOR Rate [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate	2.00%
Term Loan A [Member]
Line of Credit Facility [Line Items]
Line of credit facility		$27,000,000
Current borrowings under credit facility		27,000,000
Term Loan B [Member]
Line of Credit Facility [Line Items]
Line of credit facility		8,000,000
Interest on the credit facility, description	Term Loan B was unfunded at closing and as of March 31, 2015 and is available for the Company to draw upon for a period of 180 days post-closing in respect of a Permitted Acquisition.
Line of credit facility, borrowings period	180 days
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit facility		10,000,000
Current borrowings under credit facility	1,000,000		566,000
CBFR Loans [Member]
Line of Credit Facility [Line Items]
Interest on the credit facility, description	CBFR Loans which bears interest at a per annum rate equal to (a) the Lender's prime rate or (b) LIBOR for a 30 day interest period plus 2.50%, in each case plus a margin ranging from -0.75% to -0.25%.
CBFR Loans [Member] | LIBOR [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate	2.50%
CBFR Loans [Member] | Maximum [Member] | LIBOR [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate	-0.75%
CBFR Loans [Member] | Minimum [Member] | LIBOR [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate	-0.25%
Credit Facility [Member]
Line of Credit Facility [Line Items]
Minimum fixed charge coverage ratio	1.25
Minimum net worth	37,500,000
Credit Facility [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Maximum leverage ratio	3
Credit Facility [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Maximum leverage ratio	2.25

Debt_Summary_of_Revolver_Based

Debt - Summary of Revolver Based upon Company's Eligible Accounts Receivable and Inventory (Detail) (Revolving Credit Facility [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Gross Availability	$10,000	$7,432
Outstanding Draws	-1,000	-566
Letter of Credit		-282
Availability on Revolver	$9,000	$6,584

Debt_Summary_of_Future_Maturit

Debt - Summary of Future Maturities of Loans and Capital Leases (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Line of Credit Facility [Line Items]
2015	$3,907
2016	7,145
2017	5,094
2018	3,981
2019	3,860
2020	9,630
Total	33,617	25,484
Term Loans [Member]
Line of Credit Facility [Line Items]
2015	1,930
2016	3,860
2017	3,860
2018	3,860
2019	3,860
2020	9,630
Total	27,000	20,087
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
2016	1,000
Total	1,000	566
Capital Lease Obligations [Member]
Line of Credit Facility [Line Items]
2015	1,977
2016	2,285
2017	1,234
2018	121
Total	$5,617	$4,831

Debt_Summary_of_Companys_Curre

Debt - Summary of Company's Current and Long-Term Debt (Including Capital Leases) (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Line of Credit Facility [Line Items]
Current portion of long-term debt	$5,537	$6,452
Long-Term Debt	28,080	19,032
Total	33,617	25,484
Term Loans [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt	2,895	4,238
Long-Term Debt	24,105	15,849
Total	27,000	20,087
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Long-Term Debt	1,000	566
Total	1,000	566
Capital Lease Obligations [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt	2,642	2,214
Long-Term Debt	2,975	2,617
Total	$5,617	$4,831

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Income tax benefit (expense)	$285	($349)
Effective income tax rate	40.80%	37.40%

Loss_Earnings_Per_Share_Numera

(Loss) Earnings Per Share - Numerators and Denominators of Basic and Diluted (Loss) Income per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Net (loss) income	($415)	$583
Weighted average common shares outstanding:
Basic	22,308,730	21,972,739
Dilutive effect of restricted shares, options and non-vested share awards	446,283	483,404
Diluted	22,308,730	22,456,143
Net (loss) income per share:
Basic	($0.02)	$0.03
Diluted	($0.02)	$0.03

Loss_Earnings_Per_Share_Additi

(Loss) Earnings Per Share - Additional Information (Detail) (Stock Options [Member])	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares with anti-dilutive effect	0.3	0.1

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (Subsequent Events [Member], Ciscura [Member], USD $)	0 Months Ended
	Apr. 21, 2015	Apr. 21, 2015
	Medical_Facility
	InfusionPump
Subsequent Event [Line Items]
Number of infusion pumps acquired	1,600
Number of medical facility relationships prior to acquisition	106
Estimated integration and transaction costs	$500,000	$500,000
Maximum [Member]
Subsequent Event [Line Items]
Estimated acquisition value	$5,000,000	$5,000,000